“Coherent Market Insights announced that it’s published an exclusive report namely Global Conjugate Vaccine Market by Manufacturers, Regions, Type, and Application, Forecast to 2028 in its research database with report summary, table of content, research methodologies, and data sources. The research study offers a substantial knowledge platform for entrants and investors as well as veteran companies, manufacturers functioning in the Worldwide Conjugate Vaccine Market. This is an informative study covering the market with an in-depth analysis and portraying the current state of affairs in the industry.”
Get Latest Insights in Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/2697
A conjugate vaccine is used in order to invoke an immune system response against the weak antigen. These vaccines target several major causes of vaccine-preventable deaths, and offer vaccination against a variety of bacterial strains. According to the Centers for Disease Control and Prevention (CDC), pneumococcal conjugate vaccine (named PCV13) protects against 13 types of pneumococcal bacteria.
High prevalence of infectious diseases across the globe is expected to augment the growth of the global conjugate vaccine market during the forecast period. For instance, as per the World Health Organization (WHO), as of November 2017, around 280 million people in 21 African belt countries have been vaccinated with the meningococcal A conjugate vaccine.
Moreover, high prevalence of meningococcal infections is expected to propel growth of the global conjugate vaccine market. For instance, according to the CDC, in 2015, over 375 cases of meningococcal disease were reported in the United States.
Furthermore, introduction of novel products or frequent approvals/launches of novel products are expected to drive growth of the global conjugate vaccine market during the forecast period. For instance, in September 2018, Pfizer announced that the U.S. Food and Drug Administration (USFDA) has approved its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077. It is indicated for the prevention of invasive disease and pneumonia, caused by Streptococcus pneumonia serotypes in adults 18 years of age and older.
Whereas, in December 2016, Pfizer Inc. announced that the European Commission (EC) has approved an expanded indication for Nimenrix (conjugate vaccine) for active immunization against invasive meningococcal disease (IMD) in infants as early as six weeks of age.
By Product Types:
- Monovalent Conjugate Vaccines
- Multivalent Conjugate Vaccine
By Disease Indication:
By Pathogen Type:
By Patient Type:
- North America
- Latin America
- Asia Pacific
- Middle East
Buy This Research Study Report (Flat US $2000 OFF) @ https://www.coherentmarketinsights.com/promo/buynow/2697
Among regions, North America is expected to witness robust growth in the market due to the high prevalence of infectious diseases and the presence of major vaccines manufacturers in the region, especially in the U.S. For instance, as per the National Health Interview Survey (NHIS), in 2015, risk of pneumococcal disease among American adults aged 19 to 64 years increased by around 2.8%, as compared 2014.
Moreover, Asia Pacific is expected to witness significant growth in the market due to initiatives taken by national governments, hospitals, and healthcare providers to increase vaccination. For instance, Mission Indradhanush (vaccination program) by Indian Government and the National Immunization Program by Queensland Government in Australia work to provide vaccination among children in the respective countries.
Furthermore, Europe is also expected to witness substantial growth in the market due increase in development of conjugate vaccines in this region. For instance, in March 2015, Pfizer Inc. received the European Commission approval for an expanded indication for the use of Prevenar 13 (conjugate vaccine) for prevention of pneumonia in adults aged 18 years and older.
Major Players Are Operating In The Market: Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, and Bio-Med
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027